Skip to Content
Merck
  • Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer.

Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer.

Reproductive biomedicine online (2014-12-03)
Maria Martinez, Susana Rabadan, Javier Domingo, Ana Cobo, Antonio Pellicer, Juan A Garcia-Velasco
ABSTRACT

Obstetric outcome of first pregnancies achieved after vitrification and warming oocytes from women being treated for cancer was evaluated. Of a total of 493 women who consulted for fertility preservation, 357 had their oocytes cryopreserved after being diagnosed with cancer, and 11 returned after being cured for assisted reproduction treatments (eight had breast cancer, one Hodgkin lymphoma, one endometrial adenocarcinoma, and one thyroid cancer). The oocyte survival rate was 92.3%, the fertilization rate was 76.6%, and the mean number of embryos transferred was 1.8 ± 0.7. Beta-human chorionic gonadotropin was detected in seven out of the 11 embryo transfers carried out. Four ongoing pregnancies were achieved and delivered at term with normal fetal weight and no major or minor malformations. Women diagnosed with cancer who have their eggs cryopreserved before anti-cancer treatment have good assisted reproductive technology performance and good perinatal outcomes. Cryopreservation of oocytes seems to be a good alternative for fertility preservation in these women.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Luteinizing hormone releasing hormone salmon, ≥97% (HPLC)
Sigma-Aldrich
Letrozole, ≥98% (HPLC)
Supelco
Letrozole, Pharmaceutical Secondary Standard; Certified Reference Material
Letrozole, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Luteinizing hormone releasing hormone, ≥97% (HPLC)